Page 79 - 《中国药房》2025年22期

Sequence variations in PCSK9，low LDL，and protection ken= &siteCode=bm24000006&searchWord= % E5%B9%
against coronary heart disease[J]. N Engl J Med，2006，354 B4%E9%89%B4&button=.
（12）：1264-1272. [21] 沈瑛莹. 瑞舒伐他汀在心血管疾病一级预防的药物经济
[ 8 ] SABATINE M S，GIUGLIANO R P，KEECH A C，et al. 学评价[D]. 沈阳：中国医科大学，2021.
Evolocumab and clinical outcomes in patients with cardio‐ [22] WANG L，WU Y Q，TANG X，et al. Profile and correlates
vascular disease[J]. N Engl J Med，2017，376（18）：1713-1722. of health-related quality of life in Chinese patients with
[ 9 ] 中国血脂管理指南修订联合专家委员会. 中国血脂管理 coronary heart disease[J]. Chin Med J（Engl），2015，128
指南：2023年 [J]. 中国循环杂志，2023，38（3）：237-271. （14）：1853-1861.
[10] LIU H H，LI S，LI J J. Tafolecimab，a third monoclonal an‐ [23] MATZA L S，STEWART K D，GANDRA S R，et al. Acute
tibody for PCSK9 as the novel lipid-lowering drug around and chronic impact of cardiovascular events on health
the world：a narrative review[J]. Drugs，2025，85（5）： state utilities[J]. BMC Health Serv Res，2015，15：173.
627-642. [24] KAZI D S，MORAN A E，COXSON P G，et al. Cost-
[11] HUO Y，CHEN B J，LIAN Q F，et al. Tafolecimab in effectiveness of PCSK9 inhibitor therapy in patients with
Chinese patients with non-familial hypercholesterolemia heterozygous familial hypercholesterolemia or athero-
（CREDIT-1） ：a 48-week randomized，double-blind， sclerotic cardiovascular disease[J]. JAMA，2016，316（7）：
placebo-controlled phase 3 trial[J]. Lancet Reg Health 743-753.
West Pac，2023，41：100907. [25] 刘国恩，胡善联，吴久鸿，等. 中国药物经济学评价指南
[12] CHAI M，HE Y M，ZHAO W，et al. Efficacy and safety of [M]. 北京：中国市场出版社，2020：27.
tafolecimab in Chinese patients with heterozygous fami- [26] WAN Y S，LIU J Y，ZHAN X L，et al. Cost-effectiveness
lial hypercholesterolemia：a randomized，double-blind， and price threshold analysis of tafolecimab in Chinese pa‐
placebo-controlled phase 3 trial（CREDIT-2）[J]. BMC tients with elevated LDL cholesterol despite statin therapy
Med，2023，21（1）：77. [J]. Am J Cardiovasc Drugs，2025，25（4）：547-561.
[13] QI L T，LIU D X，QU Y L，et al. Tafolecimab in Chinese [27] ARRIETA A，HONG J C，KHERA R，et al. Updated cost-
patients with hypercholesterolemia（CREDIT-4）：a ran‐ effectiveness assessments of PCSK9 inhibitors from the
domized，double-blind，placebo-controlled phase 3 trial[J]. perspectives of the health system and private payers：in‐
JACC Asia，2023，3（4）：636-645. sights derived from the FOURIER trial[J]. JAMA Cardiol，
[14] XIE W W，SONG Y Y，QIN X M，et al. Cost- 2017，2（12）：1369-1374.
effectiveness of evolocumab in adult patients with athero‐ [28] KODERA S，MORITA H，KIYOSUE A，et al. Cost-
sclerotic cardiovascular disease from Chinese healthcare effectiveness of PCSK9 inhibitor plus statin in patients
perspective[J]. Adv Ther，2023，40（2）：489-503. with triple-vessel coronary artery disease in Japan[J]. Circ
[15] FONAROW G C，KEECH A C，PEDERSEN T R，et al. J，2018，82（10）：2602-2608.
Cost-effectiveness of evolocumab therapy for reducing [29] KONGPAKWATTANA K，ADEMI Z，CHAIYASOTHI T，
cardiovascular events in patients with atherosclerotic car‐ et al. Cost-effectiveness analysis of non-statin lipid-
diovascular disease[J]. JAMA Cardiol，2017，2（10）：1069- modifying agents for secondary cardiovascular disease
1078. prevention among statin-treated patients in Thailand[J].
[16] 赵晨颖. 依洛尤单抗治疗动脉粥样硬化性心血管疾病的 Pharmacoeconomics，2019，37（10）：1277-1286.
成本效果分析[D]. 石家庄：河北医科大学，2021. [30] FONAROW G C，VAN HOUT B，VILLA G，et al. Up‐
[17] COLLABORATION C T T，BAIGENT C，BLACKWELL dated cost-effectiveness analysis of evolocumab in pa‐
L，et al. Efficacy and safety of more intensive lowering of tients with very high-risk atherosclerotic cardiovascular
LDL cholesterol：a meta-analysis of data from 170 000 disease[J]. JAMA Cardiol，2019，4（7）：691-695.
participants in 26 randomised trials[J]. Lancet，2010，376 [31] MOHIUDDIN S G，WARD M E，HOLLINGWORTH W，
（9753）：1670-1681. et al. Cost-effectiveness of routine monitoring of long-
[18] WILSON P W F，SR R D，BHATT D L，et al. An interna‐ term conditions in primary care：informing decision mo-
tional model to predict recurrent cardiovascular disease[J]. delling with a systematic review in hypertension，type 2
Am J Med，2012，125（7）：695-703.e1. diabetes and chronic kidney disease[J]. Pharmacoecon
[19] DANESE M D，PEMBERTON-ROSS P，CATTERICK D， Open，2024，8（3）：359-371.
et al. Estimation of the increased risk associated with re‐ [32] HULTKRANTZ L. Discounting in economic evaluation
current events or polyvascular atherosclerotic cardiovascu‐ of healthcare interventions：what about the risk term?[J].
lar disease in the United Kingdom[J]. Eur J Prev Cardiol， Eur J Health Econ，2021，22（3）：357-363.
2021，28（3）：335-343. （收稿日期：2025-07-08 修回日期：2025-10-31）
[20] 国家卫生健康委. 2023中国卫生健康统计年鉴[EB/OL]. （编辑：孙 冰）
（2025-01-24）[2025-06-25]. https：//zs. kaipuyun. cn/s? to‐

中国药房 2025年第36卷第22期 China Pharmacy 2025 Vol. 36 No. 22 · 2821 ·